Alterity Advances ATH434 Phase 3 Preparations After FDA Trial Design Agreement
ATH: $0.265 +1.92% · MC: $57M
Alterity Therapeutics says FDA meeting minutes confirmed agreement on the proposed Phase 3 trial design for ATH434 in multiple system atrophy, and operational preparations are underway. The FDA indicated that a single pivotal trial plus confirmatory evidence could support approval, although approval is not assured. Alterity is evaluating funding and partnering alternatives and ended the quarter with approximately $41 million in cash, including a tax refund and proceeds from option exercises. A new US patent for ATH434 extends protection to 2045.

Comments